The hyperparathyroidism-jaw tumour (HPT-JT) syndrome

Clinical Cases in Mineral and Bone Metabolism

Volumn 3, Issue 2, 2006, Pages 167-174

  Bradley, Karin J ^a   Thakker, Rajesh V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HRPT2 mutations; PARAFIBROMIN; Parathyroid carcinoma; Parathyroid tumours; Tumour suppressor

Indexed keywords

FUNGAL PROTEIN; NUCLEAR PROTEIN; PROTEIN PAF1; PROTEIN PARAFIBROMIN; RNA POLYMERASE II; UNCLASSIFIED DRUG;

CHROMOSOME 1Q; CLINICAL FEATURE; DNA POLYMORPHISM; EXON; GENE; GENETIC SCREENING; GENOTYPE; HRPT2 GENE; HUMAN; JAW TUMOR; MOLECULAR GENETICS; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID TUMOR; PATHOGENESIS; PHENOTYPE; PRIMARY HYPERPARATHYROIDISM; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SOMATIC MUTATION;

EID: 33845239230     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (59)

1. Rubin MR, Silverberg SJ. Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle. J Clin Endocrinol Metab. 2005;90:5505-5507.
2. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. Journal of Bone and Mineral Research. 2002;17Suppl 2:N18-23.
3. Thakker RV, Juppner H. Genetic Disorders of Calcium Homeostasis Caused by Abnormal Regulation of Parathyroid Hormone Secretion or Responsiveness. In: DeGroot LJ, Jameson JL, ed. Endocrinology. 5th ed. Philadelphia, USA: Elsevier Saunders. 2006:1511-1531.
4. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863-1875.
5. Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2003;253:634-642.
6. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40:657-663.
7. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidtsm and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108:1006-1012; discussion 1012-1003.
8. Szabo J, Heath B, Hill VM, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet. 1995;56:944-950.
9. Teh BT, Farnebo F, Kristoffersson U, et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab. 1996;81:4204-4211.
10. Cavaco BM, Barros L, Pannett AA, et al. The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. QJM. 2001;94:213-222.
11. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676-680.
12. Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. Journal of Internal Medicine. 2005;257:18-26.
13. Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore). 2002;81:1-26.
14. Hobbs MR, Pole AR, Pidwirny GN, et al. Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q, Am J Hum Genet. 1999;64:518-525.
15. Cetani F, Pardi E, Borsari S, et al. Genetic Analyses of the HRPT2 Gene in Primary Hyperparathyroidism: Germline and Somatic Mutations in Familial and Sporadic Parathyroid Tumors. J Clin Endocrinol Metab. 2004;89:5583-5591.
16. Cetani F, Pardi E, Giovannetti A, et al. Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism, Clin Endocrinol (Oxf). 2002;56:457-464.
17. Bradley KJ, Cavaco BM, Bowl MR, et al. Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. J Med Genet. 2005;42:e51-55.
18. Villablanca A, Calender A, Forsberg L, et al. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004;41:e32-38.
19. Teh BT, Farnebo F, Twigg S, et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab. 1998;83: 2114-2120.
20. Moon SD, Park JH, Kim EM, et al. A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2005;90:878-883.
21. Wassif WS, Farnebo F, Teh BT, et al. Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf). 1999;50:191-196.
22. Williamson C, Cavaco BM, Jauch A, et al. Mapping the gene causing hereditary primary hyperparathyroidism in a Portuguese kindred to chromosome 1q22-q31. J Bone Miner Res. 1999;14:230-239.
23. Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89:96-102.
24. Cavaco BM, Guerra L, Bradley KJ, et al. Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab. 2004;89:1747-1752.
25. Haven CJ, Wong FK, van Dam EW, et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2000;85:1449-1454.
26. Law WM Jr, Hodgson SF, Heath H 3rd. Autosomal recessive inheritance of familial hyperparathyroidism. N Engl J Med. 1983;309:650-653.
27. Thakker RV. Multiple Endocrine Neoplasia Type 1. In: DeGroot LJ and Jameson LJ, ed. Endocrinology. 5th ed. Philadelphia, USA: Elsevier Saunders; 2006:3509-3531.
28. Weinstein LS, Simonds WF. HRPT2, a marker of parathyroid cancer. N Engl J Med. 2003;349:1691-1692.
29. Bradley KJ, Cavaco BM, Bowl MR, et al. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf). 2006;64:299-306.
30. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
31. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
32. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004;64:7405-7411.
33. Teh BT, Esapa CT, Houlston R, et al. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet. 1998;63:1544-1549.
34. Krebs LJ, Shattuck TM, Arnold A. HRPT2 Mutational Analysis of Typical Sporadic Parathyroid Adenomas. J Clin Endocrinol Metab. 2005;90:5015-5017.
35. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, et al. The parafibromin tumor suppressor protein is part of a human paf1 complex. Mol Cell Biol. 2005;25:612-620.
36. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629-6637.
37. Woodard GE, Lin L, Zhang JH, et al. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene. 2004.
38. Hahn MA, Marsh DJ. Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene. 2005;24:6241-6248.
39. Yart A, Gstaiger M, Wirbelauer C, et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol. 2005;25:5052-5060.
40. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404-407.
41. Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr Relat Cancer. 1999;6:449-473.
42. Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu Rev Physiol. 2000;62:377-411.
43. Teh BT, Kytola S, Farnebo F, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:2621-2626.
44. Pannett AA, Kennedy AM, Turner JJ, et al. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf). 2003;58:639-646.
45. Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet. 2004;41:155-160.
46. Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med. 1998;49:15-29.
47. Pestell RG, Albanese C, Reutens AT, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999;20:501-534.
48. Mittendorf EA, McHenry CR. Parathyroid carcinoma. J Surg Oncol. 2005;89:136-142.
49. Hsi ED, Zukerberg LR, Yang WI, et al. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736-1739.
50. Yoshimoto K, Endo H, Tsuyuguchi M, et al. Familial isolated primary hyperparathyroidism with parathyroid carcinomas: clinical and molecular features. Clin Endocrinol (Oxf). 1998;48:67-72.
51. Dwight T, Nelson A, Marsh DJ, et al. Parathyroid tumourigenesis in association with primary hyperparathyroidism. Current Opinion in Endocrinology and Diabetes. 2002;9:51-60.
52. Kishikawa S, Shan L, Ogihara K, et al. Overexpression and genetic abnormality of p53 in parathyroid adenomas. Pathol Int. 1999;49:853-857.
53. Farnebo F, Kytola S, Teh BT, et al. Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab. 1999;84:3775-3780.
54. Cryns VL, Yi SM, Tahara H, et al. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosomes Cancer. 1995;13:9-17.
55. Carling T. Molecular pathology of parathyroid tumors. Trends Endocrinol Metab. 2001;12:53-58.
56. Arnold A, Brown MF, Urena P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995;95:2047-2053.
57. Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol. 1999;12:412-416.
58. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757-761.
59. Cryns VL, Rubio MP, Thor AD, et al. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab. 1994;78:1320-1324.